Abstract
Glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common X-linked enzymopathy can lead to severe hyperbilirubinemia, acute bilirubin encephalopathy and kernicterus in the United States. Neonatal testing for G6PD deficiency is not yet routine and the American Academy of Pediatrics recommends testing only in jaundiced newborns who are receiving phototherapy whose family history, ethnicity, or geographic origin suggest risk for the condition, or for infants whose response to phototherapy is poor. Screening tests for G6PD deficiency are available, are suitable for use in newborns and have been used in birth hospitals. However, US birth hospitals experience is limited and no national consensus has emerged regarding the need for newborn G6PD testing, its effectiveness or the best approach. Our review of current state of G6PD deficiency screening highlights research gaps and informs specific operational challenges to implement universal newborn G6PD testing concurrent to bilirubin screening in the United States.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Bhutani VK, Johnson LH, Jeffrey Maisels M, Newman TB, Phibbs C, Stark AR et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol 2004; 24: 650–662.
Johnson L, Bhutani VK, Karp K, Sivieri M, Shapiro SM . Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). J Perinatol 2009; 29 (S1): S25–S45.
Beutler E . Glucose-6-phosphate dehydrogenase deficiency. New Eng J Med 1991; 324: 169–174.
Beutler E . G6PD deficiency. Blood 1994; 84: 3613–3636.
Valaes T, Karaklis A, Stravrakakis D, Bavela-Stravrakakis K, Perakis A, Doxiadis SA . Incidence and mechanism of neonatal jaundice related to glucose-6-phosphate dehydrogenase deficiency. Pediatr Res 1969; 3: 448–458.
Online Mendelian Inheritance in Man [OMIM]: glucose-6-phosphate dehydrogenase; G6PD http://omim.org/entry/305900 Accessed on 10 August 2011.
Beutler E . G6PD. population genetics and clinical manifestations. Blood Rev 1996; 10: 45–52.
Cappellini MD, Fiorelli G . Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008; 371: 64–74.
Subcommittee on Hyperbilirubinemia, American Academy of Pediatrics. Clinical practice guideline: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114: 297–316.
Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF . Hyperbilirubinemia in the newborn infant ⩾35 weeks’ gestation: an update with clarifications. Pediatrics 2009; 124: 1193–1198.
Lin Z, Fontaine JM, Freer DE, Naylor EW . Alternative DNA-based newborn screening for glucose-6-phosphate dehydrogenase deficiency. Mol Genet Metab 2005; 86: 212–219.
Nock ML, Johnson EM, Krugman RR, Di Fiore JM, Fitzgerald S, Sandhaus LM et al. Implementation and analysis of a pilot in-hospital newborn screening program for glucose-6-phosphate dehydrogenase deficiency in the United States. J Perinatol 2011; 31: 112–117.
Brown AK, Damus K, Kim MH, King K, Harper R, Campbell D et al. Factors relating to readmission of term and near term neonates in the first two weeks of life. J Perinat Med 1999; 27: 263–275.
Newman TB, Liljestrand P, Escobar GJ . Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns. Arch Pediatr Adolesc Med 2005; 159: 113–119.
Keren R, Bhutani VK, Luan X, Nihtianova S, Cnaan A, Schwartz JS . Identifying newborns at risk of significant hyperbilirubinemia.’. Arch Dis Child 2005; 90: 415–421.
Johnson L, Bhutani VK, Brown AK . ‘System-based approach to management of neonatal jaundice and prevention of kernicterus.’. J Pediatr 2002; 140: 396–403.
Manning DJ, Maxwell MJ, Todd PJ, Platt MJ . Prospective surveillance study of severe hyperbilirubinaemia in the newborn in the United Kingdom and Ireland. Arch Dis Child Fetal Neonatal Ed 2007; 92 (5): F342–F346.
Sgro M, Campbell D, Shah V . Incidence and causes of severe neonatal hyperbilirubinemia in Canada. CMAJ 2006; 175: 587–590.
Al Otaibi SF, Blaser S, MacGregor DL . ‘Neurological Complications of Kernicterus.’. Canadian J Neurol Sci 2005; 32: 311–315.
Sgro M, Campbell D, Barozzino T, Shah V . Acute neurological findings in a national cohort of neonates with severe neonatal hyperbilirubinemia. J Perinatol 2011; 31: 392–396.
Sgro M, Campbell DM, Kandasamy S, Shah V . Incidence of chronic bilirubin encephalopathy in Canada, 2007-2008. Pediatrics 2012; 130: e886–e890.
Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E . The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis.’. Blood Cells Mol Dis 2009; 42: 267–278.
Chinevere TD, Murray CK, Grant E, Johnson GA, Duelm F, Hospenthal DR . ‘Prevalence of glucose‐6‐phosphate dehydrogenase deficiency in U.S. Army personnel.’. Mil Med 2006; 171: 905–907.
Riskin A, Gery N, Kugelman A, Hemo M, Spevak I, Bader DJ . Glucose-6-phosphate dehydrogenase deficiency and borderline deficiency: association with neonatal hyperbilirubinemia. Pediatrics 2012; 161: 191–196.
Kaplan M, Herschel M, Hammerman C, Hoyer JD, Heller GZ, Stevenson DK . Neonatal hyperbilirubinemia in African American males: the importance of glucose-6-phosphate dehydrogenase deficiency. J of Pediatr 2006; 149: 83–88.
Fetus and Newborn Committee, Canadian Paediatric Society. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks’ gestation) - summary. Paediatr Child Health 2007; 12: 401–418.
Kaplan M, Hammerman C, Feldman R, Brisk R . Predischarge bilirubin screening in glucose-6-phosphate dehydrogenase-deficient neonates. Pediatrics 2000; 105: 533–537.
Bhutani VK . Jaundice due to glucose-6-phosphate dehydrogenase deficiency. Neoreviews 2012; 13: e166–e177.
MacDonald MG . ‘Hidden risks: early discharge and bilirubin toxicity due to glucose 6-phosphate dehydrogenase deficiency.’. Pediatrics 1995; 96: 734–738.
Kaplan M, Beutler E, Vreman HJ, Hammerman C, Levy-Lahad E, Renbaum P et al. Neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes’. Pediatrics 1999; 104: 68–74.
Kaplan M, Hammerman C . Hemolytic disorders and their management in Stevenson DK, Maisels MJ, Watchko JF, (eds) Care of the Jaundiced Neonate. The McGraw-Hill Companies: New York, USA, 2012 pp 145–173.
Kaplan M, Hammerman C . The need for neonatal glucose‐6‐phosphate dehydrogenase screening: a global perspective. J Perinatol 2009; 29 (Suppl 1): S46–S52.
Kaplan M, Hammerman C . Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicterus. Semin Perinatol 2004; 28: 356–364.
Slusher TM, Vreman HJ, McLaren DW, Lewison LJ, Brown AK, Stevenson DK . Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants. J Pediatr 1995; 126: 102–108.
Kaplan M, Renbaum P, Levy‐Lahad E, Hammerman C, Lahad A, Beutler E . Gilbert syndrome and glucose‐6‐phosphate dehydrogenase deficiency: a dose‐dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc Natl Acad Sci USA 1997; 94: 12128–12132.
Kaplan M, Herschel M, Hammerman C, Hoyer JD, Stevenson DK . Hyperbilirubinemia among african american, glucose-6-phosphate dehydrogenase-deficient neonates. Pediatrics 2004; 114: e213–e219.
Kaplan M, Muraca M, Vreman HJ, Hammerman C, Vilei MT, Rubaltelli FF et al. Neonatal bilirubin production-conjugation imbalance: effect of glucose-6-phosphate dehydrogenase deficiency and borderline prematurity. Arch Dis Child Fetal Neonatal Ed 2005; 90: 123–127.
Missiou-Tsagaraki S . Screening for glucose-6-phosphate dehydrogenase deficiency as a preventive measure: prevalence among 1,286,000 Greek newborn infants. J Pediatr 1991; 119: 293–299.
Hsaio KJ, Chiang S, Wu SJ, Wu KF . Experience of neonatal G6PD deficiency screening in Taiwan In: Wilcken B, Webster D, (eds) Neonatal screening in the nineties. Leura, The Kelvin Press: NSW, Australia, 1991 pp 217–218.
Mallouh AA, Imseeh G, Abu-Osba YK, Hamdan JA . Screening for glucose-6-phosphate dehydrogenase deficiency can prevent severe neonatal jaundice. Ann Trop Paediatr 1992; 12: 391–395.
Meloni T, Forteleoni G, Meloni GF . Marked decline of favism after neonatal glucose-6-phosphate dehydrogenase screening and health education: the northern Sardinian experience. Acta Haematol 1992; 87: 29–31.
Lo KK, Chan ML, Lai SSL, Li KCK, Hung P, Lam STS et al. Neonatal screening for glucose-6-phosphate dehydrogenase deficiency in Hong Kong In Lam T, Pang C, (eds) Neonatal and Perinatal Screening: the Asian Pacific Perspectives. The Chinese University Press: Hong Kong, 1995 pp 33–35.
Joseph R, Ho LY, Gomez JM, Rajdurai VS, Sivasankaran S, Yip YY . Mass newborn screening for glucose-6-phosphate dehydrogenase deficiency in Singapore. Southeast Asian J Trop Med Public Health 1999; 30 (Suppl 2): 70–71.
Padilla CD . ‘Newborn screening in the Philippines.’. Southeast Asian J Trop Med Public Health 2003; 34 (Suppl 3): 87–88.
Padilla CD, Therrell BL . Newborn screening in the Asia Pacific region. J Inherit Metab Dis 2007; 30: 490–506.
Algur N, Avraham I, Hammerman C, Kaplan M . Quantitative neonatal glucose-6-phosphate dehydrogenase screening: distribution, reference values, and classification by phenotype. J Pediatr 2012; 161: 197–200.
Castro SM, Weber R, Dadalt V, Santos VF, Reclos GJ, Pass KA et al. Evaluation of glucose-6-phosphate dehydrogenase stability in blood samples under different collection and storage conditions. Clin Chem 2005; 51: 1080–1081.
Panepinto JA, Magid D, Rewers MJ, Lane PA . Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J Pediatr 2000; 136: 201–208.
WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ 1989; 67: 601–611.
Beutler E, Blume KG, Kaplan JC, Löhr GW, Ramot B, Valentine WN . International Committee for standardization in haematology: recommended screening test for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Br J of Haematol 1979; 43: 465–467.
Beal AC, Chou SC, Palmer RH, Testa MA, Newman C et al. ‘The Changing Face of Race: Risk Factors for Neonatal Hyperbilirubinemia.’. Pediatrics 2006; 117: 1618–1625.
Fairbanks VF, Fernandez MN . The Identification of Metabolic Errors Associated With Hemolytic Anemia. JAMA 1969; 208: 316–320.
Watchko JF . Hyperbilirubinemia in African American neonates: clinical issues and current challenges. Semin Fetal Neonatal Med 2010; 15: 176–182.
Kaplan M, Beutler E, Vreman HJ, Hammerman C, Levy‐Lahad E, Renbaum P et al. Neonatal hyperbilirubinemia in glucose‐6‐ phosphate dehydrogenase‐deficient heterozygotes. Pediatrics 1999; 104: 68–74.
Bhutani VK, Sivieri EM, Johnson L . Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999; 103: 6–14.
Kappas A, Drummond GS, Valaes T . A single dose of Sn-mesoporphyrin prevents development of severe hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns. Pediatrics 2001; 108: 25–30.
Acknowledgements
This manuscript derives in part from the US Stakeholders meeting convened on 28–29 July 2010 to determine the feasibility of identification of G6PD deficiency to prevent severe hyperbilirubinemia sponsored by the Health Research Services HRSA/NNSGRC. We thank the participants of this Stakeholders Meeting for their thoughtful suggestions and ideas. These individuals include: Duane Alexander (National Institute of Health, NIH), Hani Atrash and Wanda Barfield (Center for Disease Control, CDC), Stan Berberich (Iowa Program, HRSA Newborn Screening), Vinod K Bhutani (Lucile Packard Children’s Hospital at Stanford University), George Buchanan (University of Texas Southwestern Medical School), (Roger Eaton Massachusetts Program, HRSA Newborn Screening), Jim Eckman (Emory University, Atlanta, GA), Bertil Glader (Lucile Packard Children’s Hospital at Stanford University), Alice Gong (University of Texas Health Science Center at San Antonio), Greg Gosch (Luminex), Jeffrey S Gould (Lucile Packard Children’s Hospital at Stanford University), Nancy S Green (Columbia University, New York, NY), Scott Grosse (CDC), Judy Hall (Lucile Packard Children’s Hospital at Stanford University), Harry Hannon (CDC, Quality assurance), Jim Hanson (NIH), Keith Hoots (NHLBI), Carolyn Hoppe (Children’s Hospital of Oakland Research Institute, Oakland, CA), Rodney Howell (NIH), Lois Johnson (Pennsylvania Center for Kernicterus), Michael Kaplan (Shaare-Zadek Hospital, Jerusalem, Israel), Fred Lorey (CDC, Newborn Screening), Marie Mann (HRSA), Mary Nock (Macdonald Hospital, Case Western Reserve University), Kwaku Ohene-Frempong (Children’s Hospital of Philadelphia, University of Pennsylvania), Richard Olney (CDC), Vamsee Pamula (Advanced Liquid Logics, Durham, NC), Michele Parisi (NIH), Leela Phillip and Family (Patient with G6PD and Kernicterus with her family), Michele Puryear (HRSA), Tonse NK Raju (NICHD), Keld Sorenson (Luminex), Ann R. Stark (Safe and Healthy Beginnings Initiative, American Academy of Pediatrics, Baylor College of Medicine), David K Stevenson (Lucile Packard Children’s Hospital at Stanford University), Brad Therrell (NNSGRC), Tina Urv (NIH), Peter van Dyck (HRSA, MCHB) and Jon F Watchko (Magee Women’s Hospital, University of Pittsburgh). We gratefully appreciate the individual contributions of Drs Nancy S Green, Bertil Glader, Marie Mann, Bradley Therrell and Lois Johnson, and their constructive critique of an earlier version of this manuscript. We thank Rohan Vilms and Diana Wise (research assistants) at the Stanford University. We also acknowledge and thank Stella Gengania-Dina and Ronald J Wong for their administrative support at the Stanford University.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Watchko, J., Kaplan, M., Stark, A. et al. Should we screen newborns for glucose-6-phosphate dehydrogenase deficiency in the United States?. J Perinatol 33, 499–504 (2013). https://doi.org/10.1038/jp.2013.14
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jp.2013.14
Keywords
This article is cited by
-
Causes of severe neonatal hyperbilirubinemia: a multicenter study of three regions in China
World Journal of Pediatrics (2021)
-
The association between glucose-6-phosphate dehydrogenase deficiency and abnormal blood pressure among prepregnant reproductive-age Chinese females
Hypertension Research (2019)
-
Indirect neonatal hyperbilirubinemia in hospitalized neonates on the Thai-Myanmar border: a review of neonatal medical records from 2009 to 2014
BMC Pediatrics (2018)
-
The African-American neonate at risk for extreme hyperbilirubinemia: a better management strategy is needed
Journal of Perinatology (2017)
-
Parental education and the WHO neonatal G-6-PD screening program: a quarter century later
Journal of Perinatology (2015)